MVR-T7011

MVR-T7011 is an investigational **oncolytic herpes simplex virus therapy** from ImmVira designed as a CAR-T enabler for solid tumors. The product uses an engineered oHSV vector to infect tumor cells and drive membrane expression of the extracellular domains of **CD19** and **BCMA**, thereby creating artificial CAR-recognizable antigens on solid tumor cells so that existing CD19- or BCMA-directed CAR-T approaches may be redirected against solid malignancies. The construct also encodes **CCL5**, a **PD-1 antibody**, and **IL-12** to enhance immune-cell recruitment and antitumor immune activation while supporting direct oncolytic killing. Based on the provided information, the program was in preclinical development with pilot-scale manufacturing completed and IND-enabling preparation underway as of 2023.